Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Studies have shown that patients using semaglutide (Ozempic) or tirzepatide (Mounjaro) can lose up to 15-20% of their body weight with proper medical supervision and lifestyle changes
Cleanses and nourishes the skin while maintaining its natural moisture balance
Both Semaglutide GLP-1 (Ozempic and Wegovy) and Tirzepatide (Mounjaro) were originally created for use in treatment for those with type 2 diabetes to help manage the condition but were quickly realized to have fantastic weight loss benefits as well, which is why they are both so frequently used as part of weight loss treatments
In the meantime, CMS (Centers for Medicare & Medicaid Services) created two demonstration programs: Medicare GLP-1 Bridge (July 2026 to December 2027): A short-term program providing Medicare Part D beneficiaries access to select FDA-approved GLP-1 medications for obesity at a $50 monthly copay
